GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf life of NARCAN® (naloxone HCl) Nasal Spray from 24 months to 36 months. Narcan Nasal Spray was the first intranasal form of naloxone approved by FDA and Health Canada for the emergency treatment of known or suspected opioid overdose.
{iframe}https://www.globenewswire.com/news-release/2020/08/17/2079086/0/en/Emergent-BioSolutions-Announces-FDA-Approval-of-NARCAN-naloxone-HCl-Nasal-Spray-Shelf-Life-Extension-to-36-Months.html{/iframe}